<International Circulation>: Regarding future areas of research， where do you feel this area is headed?

   《国际循环》： 至于未来的研究领域，您认为这一领域将走向何方？
    Prof.Swedberg: Of course， everyone would like to know if Ivabradine could replace beta-blockers， but I think that trial would be very difficult.  That would be very interesting because Ivabradine is so much easier to use.  At least， instead of trying to maximize the dose of a beta-blocker you could at some stage give Ivabradine and assess it’s effect on outcomes with sub-maximal beta-blocker dosage.  A trial of this nature would be extremely important and of great clinical meaning because Ivabradine is so much simpler to use.

    Prof.Swedberg:当然，每个人都想要治疗伊伐布雷定是否能替代β受体阻滞剂，但我认为，这个试验会非常困难。那将会令人很感兴趣，因为伊伐布雷定更易使用。 至少，在某个阶段你可以在β受体阻滞剂次最大剂量的基础上给予伊伐布雷定并评估其对结果的影响，而不是尝试最大化β受体阻滞剂的剂量 。这种性质的试验将会是极其重要的，且有重大的临床意义，因为伊伐布雷定用起来要简单得多。

crack

上一页  [1]  [2]  [3]